Clarius Group LLC Sells 206 Shares of Cardinal Health, Inc. $CAH

Clarius Group LLC trimmed its holdings in Cardinal Health, Inc. (NYSE:CAH) by 8.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,271 shares of the company’s stock after selling 206 shares during the period. Clarius Group LLC’s holdings in Cardinal Health were worth $382,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in shares of Cardinal Health by 40.0% in the first quarter. JPMorgan Chase & Co. now owns 4,175,992 shares of the company’s stock valued at $575,327,000 after buying an additional 1,193,983 shares during the last quarter. Northern Trust Corp lifted its position in shares of Cardinal Health by 3.5% in the first quarter. Northern Trust Corp now owns 3,143,003 shares of the company’s stock valued at $433,012,000 after buying an additional 105,154 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Cardinal Health by 1,666.7% in the first quarter. Wellington Management Group LLP now owns 2,384,192 shares of the company’s stock valued at $328,470,000 after buying an additional 2,249,241 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Cardinal Health by 3.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,654,036 shares of the company’s stock valued at $227,877,000 after buying an additional 52,714 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Cardinal Health by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,246,788 shares of the company’s stock valued at $171,749,000 after buying an additional 7,940 shares during the last quarter. 87.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CAH has been the topic of a number of recent research reports. Argus set a $189.00 target price on Cardinal Health in a research note on Friday, August 22nd. Citigroup reiterated a “neutral” rating and set a $170.00 target price (up previously from $157.00) on shares of Cardinal Health in a research note on Friday, June 13th. Evercore ISI lowered their target price on Cardinal Health from $200.00 to $190.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen lowered Cardinal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $185.00 target price (up previously from $183.00) on shares of Cardinal Health in a research note on Wednesday, August 13th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Cardinal Health presently has a consensus rating of “Moderate Buy” and an average price target of $166.00.

Insider Transactions at Cardinal Health

In other Cardinal Health news, insider Jessica L. Mayer sold 38,078 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $148.82, for a total value of $5,666,767.96. Following the sale, the insider owned 48,457 shares of the company’s stock, valued at approximately $7,211,370.74. This trade represents a 44.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jason M. Hollar sold 35,901 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $150.04, for a total value of $5,386,586.04. Following the completion of the sale, the chief executive officer directly owned 200,000 shares in the company, valued at approximately $30,008,000. This represents a 15.22% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 271,676 shares of company stock worth $40,489,525. 0.12% of the stock is owned by insiders.

Cardinal Health Price Performance

Shares of NYSE:CAH opened at $155.25 on Tuesday. The company has a market capitalization of $36.88 billion, a P/E ratio of 24.07, a P/E/G ratio of 1.31 and a beta of 0.71. Cardinal Health, Inc. has a 1 year low of $106.98 and a 1 year high of $168.44. The business’s 50 day simple moving average is $152.05 and its 200 day simple moving average is $150.67.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Tuesday, August 12th. The company reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The business had revenue of $60.16 billion for the quarter, compared to the consensus estimate of $60.91 billion. Cardinal Health had a negative return on equity of 74.45% and a net margin of 0.70%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.84 earnings per share. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. On average, sell-side analysts anticipate that Cardinal Health, Inc. will post 7.95 EPS for the current fiscal year.

Cardinal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be issued a $0.5107 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is currently 31.63%.

Cardinal Health Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.